ArticleImmunity, inflammation and disease2026
Predicting Role of Interleukin-33 in Determining the Development and Severity of Atopic Dermatitis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rewiring Atopic Dermatitis: Alarmin Cytokines at the Core of Barrier-Immune-Neuro-Microbiome Networks.Clinical reviews in allergy & immunology · 2026Review
- Predicting Role of Interleukin-33 in Determining the Development and Severity of Atopic Dermatitis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAtopic dermatitis (AD), also referred to as atopic eczema, is one of the most common immunological disorders in children. Previous studies have suggested potential roles of interleukin-33 (IL-33) in the onset and progression of AD. This study investigated whether serum IL-33 levels in children with AD are associated with disease severity, immunoglobulin E (IgE) sensitization to food or environmental allergens, and serum IgE concentration.
methodsThe study included 62 children with newly diagnosed AD and 30 age-matched healthy controls. Following an interview and confirmation of disease severity, 3mL of venous blood was collected from each participant. Sensitization to allergens was assessed using a skin prick test. Serum IL-33 (ng/L) and IgE (IU/mL) levels were measured using enzyme-linked immunosorbent assay (ELISA).
resultsAmong the 62 children with AD, 51 (82.3%) were sensitized to food allergens, whereas 11 (17.7%) were sensitized to environmental allergens. Most patients (75.8%) had mild AD. Serum IL-33 and IgE levels were significantly elevated in patients compared with healthy controls. Both IL-33 and IgE concentrations were significantly associated with moderate AD. However, IL-33 levels were not correlated with age, gender, or allergen type. Receiver operating characteristic (ROC) analysis revealed that IgE levels demonstrated moderate diagnostic performance for AD (AUCc0.758), while IL-33 showed weaker diagnostic value (AUC = 0.678). For predicting disease severity, IL-33 exhibited strong performance, with the highest sensitivity (85.71%) and maximum specificity (70.21%) at a cut-off of 331.32 ng/L (AUC = 0.862). In contrast, IgE was not a reliable predictor of AD severity.
conclusionSerum IL-33 levels are significantly correlated with AD severity and may serve as a predictive biomarker, whereas IgE shows limited utility for severity assessment. Further studies are warranted to validate the clinical applicability of IL-33 in AD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.